Genflow Biosciences ^Company

Public longevity biotech company developing gene therapies that modulate longevity-associated genes, particularly variants of SIRT6. Founded in 2020 and headquartered in the UK and Belgium, Genflow aims to delay the onset of age-related diseases and extend healthspan through safe, durable in-vivo expression. It is listed on the London Stock Exchange (GENF). (genflowbio.com)